ImmunoCellular Therapeutics Ltd  

(Public, NYSEMKT:IMUC)   Watch this stock  
Find more results for IMUC
-0.018 (-3.13%)
Feb 27 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.57 - 0.60
52 week 0.53 - 1.46
Open 0.59
Vol / Avg. 681,899.00/634,371.00
Mkt cap 49.89M
P/E     -
Div/yield     -
EPS -0.12
Shares 87.53M
Beta 1.19
Inst. own 5%
Mar 11, 2015
Q4 2014 ImmunoCellular Therapeutics Ltd Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 10, 2015
ImmunoCellular Therapeutics Ltd at ROTH Conference - 11:30AM EDT - Add to calendar
Jan 12, 2015
ImmunoCellular Therapeutics Ltd at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -28.86% -31.45%
Return on average equity -31.45% -35.53%
Employees 3 -
CDP Score - -


23622 Calabasas Rd Ste 300
CALABASAS, CA 91302-1672
United States - Map
+1-818-2642300 (Phone)
+1-818-2245287 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient�s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. The Company�s products include ICT-107, ICT-140, ICT-121, ICT-109 and DIAAD. ICT-107, the pipeline product, is a Phase II therapeutic dendritic cell (DC) vaccine for the treatment of glioblastoma multiforme (GBM), the common and lethal type of brain cancer. ICT-107 is designed to activate a patient�s immune system to target six different tumor-associated antigens. In February 2012, it acquired a world-wide license from the University of Pennsylvania and The John Hopkins University (JHU).

Officers and directors

John S. Yu M.D. Chairman of the Board, Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters
Andrew Gengos President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Anthony J. Gringeri Ph.D. Senior Vice President - Strategic Resources
Age: 60
Bio & Compensation  - Reuters
David E. Fractor Principal Accounting Officer, Vice President - Finance
Age: 54
Bio & Compensation  - Reuters
Rahul Singhvi Lead Independent Director
Age: 49
Bio & Compensation  - Reuters
Richard H. Chin M.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Gary S. Titus Independent Director
Age: 54
Bio & Compensation  - Reuters